Pharmacokinetic and safety evaluation of multiple lasmiditan dosage
Key messages
- Lasmiditan is a novel, highly selective, potent serotonin (5-HT)1F receptor agonist, approved in the United States for the acute treatment of adult migraine with or without aura.
- Repeat doses of lasmiditan do not present any new safety issues and are well tolerated.
- There is no accumulation of lasmiditan with daily dosing due to its short half-life.
- Although in-vitro data suggested lasmiditan may induce some cytochrome P450 (CYP) enzymes, the in-vivo results have not shown this to be the case.